|Application ||WB, E|
|Calculated MW||81641 Da|
|Antigen Region||50-79 aa|
|Other Names||Transmembrane channel-like protein 8, Epidermodysplasia verruciformis protein 2, TMC8, EVER2, EVIN2|
|Target/Specificity||This TMC8 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 50-79 amino acids from the N-terminal region of human TMC8.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||TMC8 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Probable ion channel.|
|Cellular Location||Endoplasmic reticulum membrane; Multi-pass membrane protein|
|Tissue Location||Expressed in placenta, prostate and testis.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Epidermodysplasia verruciformis (EV) is an autosomal recessive dermatosis characterized by abnormal susceptibility to human papillomaviruses (HPVs) and a high rate of progression to squamous cell carcinoma on sun-exposed skin. EV is caused by mutations in either of two adjacent genes located on chromosome 17q25.3. Both of these genes encode integral membrane proteins that localize to the endoplasmic reticulum and are predicted to form transmembrane channels. This gene encodes a transmembrane channel-like protein with 8 predicted transmembrane domains and 3 leucine zipper motifs.
McDermott, D.F., et al. Pediatr Dermatol 26(3):306-310(2009)
Patel, A.S., et al. Int. J. Cancer 122(10):2377-2379(2008)
Zavattaro, E., et al. J. Invest. Dermatol. 128(3):732-735(2008)
Lazarczyk, M., et al. J. Exp. Med. 205(1):35-42(2008)
Rady, P.L., et al. Br. J. Dermatol. 157(4):831-833(2007)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.